Animal Health Asia 2020 | Kisaco Research

Animal Health Innovation Asia

Business Partnerships, Product Regulation and Market Access in Asia-Pacific

Download the Agenda
Virtual Event
24-26 November, 2020

“I think this is a great meeting for companies to come together and find out what the common challenges are and how they can work together. I’m really impressed! ”

Jishu Shi, U.S.-China Centre for Animal Health

Why Attend

Animal Health Innovation Asia is the premier business partnering conference connecting stakeholders from across Asia-Pacific that are focused on either product innovation, financial investment or strategic corporate partnerships in animal health.

Of course, given the global situation with Covid-19, this year's event will be a ‘virtual summit’, with all presentations, discussions and business meetings taking place online on our digital platform. This also allows us to broaden the discussion and involve more A-Pac regions in our annual meeting, including a large focus on the Chinese market, Japan, India, Australia and New Zealand.

Animal Health Innovation Asia provides you with the critical international business connections to support your company’s strategic growth during this time. We include keynote presentations and host C-level panel discussions that address the trends and market dynamics of the animal health industry, across all species.

200+
Attendees
21+
Private Meetings Per Person
7+
hours dedicated networking time
50+
Start-ups in attendance

Who You Will Meet

Attendees will represent the following key stakeholder groups in the Animal Health market

  • Heads of Business Development, Animal Health, R&D from Multinational Pharmaceutical Companies
  • CEOs, CSOs and Heads of Business Development from Emerging Animal Health Companies
  • CEOs, Heads of Business Development, Product Discovery and Marketing from Incubators/ Accelerators, Contract Research Orgs, Consultants, Lawyers and other Service Providers

…all of the above with an interest in Livestock, Aquaculture and the Companion Animal markets

Attendees expected from the following key stakeholder groups and organizations

Speakers

 

Mr. Rob Kelly

Executive Vice President International Operations
Zoetis Inc.

Mr. Rob Kelly

Executive Vice President International Operations
Zoetis Inc.

Mr. Rob Kelly

Executive Vice President International Operations
Zoetis Inc.
 

Mr. Mike Wang

Vice President & General Manager, Greater China
Zoetis Inc

Mike joined Zoetis (formerly Pfizer Animal Health) in May 2010 as Division Director for China. He got EMBA from CEIBS in Shanghai and has bachelor of Science in Biochemistry from Zhejiang University. Prior to Pfizer, Mike worked for Merck Human Pharmaceutical and for Becton Dickinson in China.

Mr. Mike Wang

Vice President & General Manager, Greater China
Zoetis Inc

Mr. Mike Wang

Vice President & General Manager, Greater China
Zoetis Inc

Mike joined Zoetis (formerly Pfizer Animal Health) in May 2010 as Division Director for China. He got EMBA from CEIBS in Shanghai and has bachelor of Science in Biochemistry from Zhejiang University. Prior to Pfizer, Mike worked for Merck Human Pharmaceutical and for Becton Dickinson in China.

 

Mr. Katsutoshi Kato

President
Zoetis Japan

Mr. Katsutoshi Kato

President
Zoetis Japan

Mr. Katsutoshi Kato

President
Zoetis Japan
 

Mr. Vijay Teng

Executive Vice President
INTAS Pharma

Mr. Vijay Teng

Executive Vice President
INTAS Pharma

Mr. Vijay Teng

Executive Vice President
INTAS Pharma
 

Dr. Tingwu Xue

President of China Animal Husbandry Group (CAHG) & Vice President of Chinese Veterinary Drug Association
CAHG

Dr. XUE Tingwu is the President of China Animal Husbandry Group. He has been working for the company for over 30 years, with tremendous experience and knowledge in China’s agriculture industry, China’s animal husbandry industry, China’s animal health industry. He also is the pioneer who is dedicated to promote companies which serve safety agro-products and animal-related products to Chinese publics.

Dr. Tingwu Xue

President of China Animal Husbandry Group (CAHG) & Vice President of Chinese Veterinary Drug Association
CAHG

Dr. Tingwu Xue

President of China Animal Husbandry Group (CAHG) & Vice President of Chinese Veterinary Drug Association
CAHG

Dr. XUE Tingwu is the President of China Animal Husbandry Group. He has been working for the company for over 30 years, with tremendous experience and knowledge in China’s agriculture industry, China’s animal husbandry industry, China’s animal health industry. He also is the pioneer who is dedicated to promote companies which serve safety agro-products and animal-related products to Chinese publics.

He is also actively engaged in various industry-related associations to fulfill his duty to the society. He is the key leading member of China Animal Agriculture Association, and vice-president of China Veterinary Drug Association, etc..

Plus, He is the founder and chairman of China Animal Health International Forum, which has been a platform to share information among animal health companies in order to promote the sustainable development of China animal health industry.

 

Mr. Ian Lahiffe

Country Manager - China
Antelliq

Mr. Ian Lahiffe

Country Manager - China
Antelliq

Mr. Ian Lahiffe

Country Manager - China
Antelliq
 

Mr. Toshikazu Fukui

Company President
ZENOAQ

2008 - 2011: Division Director of International Business based at the Zenoaq Beijing Representative Office

2011- 2016: Company President of Nippon Biologicals, Inc. [Zenoaq affiliate]

2013 - 2016: Executive Director of International Business [Zenoaq]

2016: Company President of Vetoquinol Zenoaq K.K.

2016 - 2018: Executive Vice President of Zenoaq

2018 - present: Company President

 

Mr. Toshikazu Fukui

Company President
ZENOAQ

Mr. Toshikazu Fukui

Company President
ZENOAQ

2008 - 2011: Division Director of International Business based at the Zenoaq Beijing Representative Office

2011- 2016: Company President of Nippon Biologicals, Inc. [Zenoaq affiliate]

2013 - 2016: Executive Director of International Business [Zenoaq]

2016: Company President of Vetoquinol Zenoaq K.K.

2016 - 2018: Executive Vice President of Zenoaq

2018 - present: Company President

 

 

Dr. Yuki Ujimasa, DVM, MS

President
AHRMS, Inc.

Dr. Yuki Ujimasa, DVM, MS

President
AHRMS, Inc.

Dr. Yuki Ujimasa, DVM, MS

President
AHRMS, Inc.
 

Mr. Kenta Yamato

CEO
Kaico Ltd

Mr. Kenta Yamato

CEO
Kaico Ltd

Mr. Kenta Yamato

CEO
Kaico Ltd
 

Dr. Tony Zi Long Tan

Founder and Managing Partner
Z-LINK BIOTECH

Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.

Dr. Tony Zi Long Tan

Founder and Managing Partner
Z-LINK BIOTECH

Dr. Tony Zi Long Tan

Founder and Managing Partner
Z-LINK BIOTECH

Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.

Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.

Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.

From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.

Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.

谭博士在动物保健领域从业超过30年,涉及各种动物品种和岗位部门,包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验,曾在美国、欧洲和亚洲(特别是中国)国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。

谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中,为牛、狗以及家禽类开发了数种疫苗,并且发表了超过50篇科学论文和研究报告。

谭博士在英特威/默沙东动物保健公司工作了超过15年,期间担任了不同职位,包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。

从2009年到2016年,谭博士在硕腾(原名辉瑞)担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易(总交易额超过一亿美元)和若干技术转让项目。其中包括中国第一个反垄断剥离项目,辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。

此外,谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。

 

Mr. Dylan Lu

Country Director, Greater China
Elanco Animal Health

Mr. Dylan Lu

Country Director, Greater China
Elanco Animal Health

Mr. Dylan Lu

Country Director, Greater China
Elanco Animal Health
 

Mr. Miles Yao

CEO
BioVantage

Miles Yao had studied virology and he holds a Master Degree in Preventive Veterinary Medicine from China Agriculture University, he also holds Master Degrees in Agricultural Economics from Purdue University, and an MBA from Indiana University-Kelley School of Business. Prior to this, he studied in Huazhong Agricultural University and earned an Animal Science Degree.

Mr. Miles Yao

CEO
BioVantage

Mr. Miles Yao

CEO
BioVantage

Miles Yao had studied virology and he holds a Master Degree in Preventive Veterinary Medicine from China Agriculture University, he also holds Master Degrees in Agricultural Economics from Purdue University, and an MBA from Indiana University-Kelley School of Business. Prior to this, he studied in Huazhong Agricultural University and earned an Animal Science Degree.

 Miles Yao founded MarketVisor AgConsulting in 2015, and since then serves as its Managing Director, responsible for market development and entry strategies, as well as day-to-day engagement with commercial, government, and trade association contacts for clients. He and his team at MarketVisor are business partners for some leading trade associations and international and domestic animal health companies.

In 2018, Miles founded BioVantage with other investing partners, committing to be a Contract Research Organization in animal health sector. 

 

Prior to being an entrepreneur, Miles has worked in leadership roles overseeing commercial and regulatory affairs with a Hong Kong based agribusiness company. He has lead China market entry strategies for agricultural products and animal health products from clients in the US, Mexico and EU. In these roles, Miles has ensured the market access, developed and managed distribution networks, key in-market client relationships and day-to day business activity. 

From 2007-2013, Miles also worked in the Beijing USDA-APHIS office promoting safe and sustainable agriculture trade in China, Hong Kong, Macau and Mongolia. His primary focuses were technical and trade consultations between Government and industry, trade barrier reduction and negotiation, and agriculture policy analysis and execution. Miles had worked with Boehringer Ingelheim Animal Health for two years during 2005-2007, while at BI, his primary focus was swine sector. He also worked in poultry sector with Beijing Efficacy Biotech Co. as a Technical Manager for some time.

 

Contact:

[email protected]

 

Mr. Wataru KURIHARA

Director, Regulatory Affairs Department
MT3

Mr. Wataru KURIHARA

Director, Regulatory Affairs Department
MT3

Mr. Wataru KURIHARA

Director, Regulatory Affairs Department
MT3
 

Mr. Koji Hori

CEO
Tolleta

Mr. Koji Hori

CEO
Tolleta

Mr. Koji Hori

CEO
Tolleta
 

Dr. Kazuya Edamura

Nihon University

Dr. Kazuya Edamura

Nihon University

Dr. Kazuya Edamura

Nihon University
 

Dr. Goshi Kato

Tokyo University of Marine Science and Technology

Dr. Goshi Kato

Tokyo University of Marine Science and Technology

Dr. Goshi Kato

Tokyo University of Marine Science and Technology
 

Mr. Lance Williams

Senior Vice President ANZ Region at Zoetis, Chair Of The Board Of Directors at Animal Medicines Australia
Zoetis

Mr. Lance Williams

Senior Vice President ANZ Region at Zoetis, Chair Of The Board Of Directors at Animal Medicines Australia
Zoetis

Mr. Lance Williams

Senior Vice President ANZ Region at Zoetis, Chair Of The Board Of Directors at Animal Medicines Australia
Zoetis
 

Mr. Simon Hellams

Vice President and Managing Director ANZ
Provet

Mr. Simon Hellams

Vice President and Managing Director ANZ
Provet

Mr. Simon Hellams

Vice President and Managing Director ANZ
Provet
 

Mr. Nigel Nichols

Animal Health Consultant

Mr. Nigel Nichols

Animal Health Consultant

Mr. Nigel Nichols

Animal Health Consultant

The Virtual Experience

Top 10 benefits

- Tailor Your Agenda 

- More Audience Participation

- Improved Audience Visibility 

- On-Demand Content

- High Quality Speakers 

- More Networking Opportunities 

- Save Time & Money 

- Increased Content 

- More insights 

- Business Development Opportunities - Talk to our team to find out out more [email protected].

Platform Preview

Testimonials

"This is a unique event for our animal health industry. It brings local and international players together, and provides an excellent platform to build business partnerships.”

Tony Zilong Tan, Z-Link Biotech Co. Ltd.

 

“This meeting is a very exciting one – it’s a platform to meet everyone from Chinese animal health and International animal health companies, and to introduce them to one-another. This way you save time and it gives you more chance to keep ahead of the innovations.”

Tingwu Xue, China Animal Husbandry Group (CAHG)

 

“I think this is a great meeting for companies to come together and find out what the common challenges are and how they can work together. I’m really impressed!"

Jishu Shi, U.S.-China Centre for Animal Health

 

"Everybody’s here, you can have many meetings in one spot, learn how to work together, increase your network and search for ideas.”
Joachim Hasenmaier, Boehringer-Ingelheim

Innovation Showcase

The Innovation Showcase will return for 2020, with start-ups presenting their novel technologies to an audience of strategic partners from APAC, Japan and around the world. These start-ups are animal health and nutrition companies who are actively seeking financial investment or strategic partnerships.

Last Year's Showcase Presenters Included:

  • Dr. Toshiyasu Miyazaki, President, Founder, MT3, Inc
    • A unique cancer-treatment product under development
  • Mr. Yukio Takene, President, J-ARM
    • Activated lymphocyte therapy and stem cell therapy
  • Mr. Kenta Yamato, CEO, Kaico Ltd
    • Vaccine antigens and diagnostic kits using genetically engineered silkworm proteins
  • Dr. Yuki Ujimasa, President, Vm3, Inc
    • A digital platform that links veterinarians with manufacturers in Japan
  • Mr. Zidong Lin, Assistant General Manager, Member of the Board, Nantong HiTide Biotechnology Co., Ltd
    • A high-tech Chinese enterprise focusing on research, development, production, sales and service of animal health related products

University Pavilion

Connecting Academia with Business Partners

The University Pavilion allows leading Universities and Technology Licencing Organisations (TLOs) from Japan to present their research and partnership opportunities in a special session on the main stage. Each instititon can bring a start-up company that is currently looking for strategic partners.

Partners

Headline Partner

Associate Partner

Start-Up Development Partner

Event Partners

Consulting Partner

Welcoming Members of... (15% Discounts available)

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

2020 Agenda

Download the 2020 agenda here.

Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

Download the Agenda

Register

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Sunday, August 25, 2019
Tier 1
$299 USD
Only 25 tickets remaining at this price point
Academics
Pre-revenue companies
Human Biotechs
Charities
Angel and Venture Capital Investors
Please note: Service providers do not qualify for this rate
Sunday, August 25, 2019
Tier 2
$799 USD
Only 25 tickets remaining at this price point
CROs & CMOs
Consultants, M&A Advisors
Private Equity Investors & Brokers
Start-Up Incubators & Accelerators
Pharmaceutical Companies
Animal Health Companies
To increase your brand presence, contact Stephen: [email protected]
Preparing registration...

Global Advisory Board

WHO THEY ARE

Each of our Advisory Board members have been chosen based on numerous recommendations, their deep knowledge and Industry experience and ability to provide a clear vision, not just for their own organizations, but for the industry as a whole.

WHY THEY ARE HERE

Board members guide not just content, but also the underlying mission of the events to drive positive change.

Author:

Marc Prikazsky

Chairman and Chief Executive Officer
CEVA Santé Animale S.A

Author:

Mr. Rob Kelly

Executive Vice President International Operations
Zoetis Inc.

Author:

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Author:

Sébastien Huron

Presidente do conselho executivo
Virbac Santé Animale

Author:

Jean-Luc Michel

Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Author:

Kathy V. Turner

Corporate Vice President and Global Chief Marketing Officer
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

Author:

George Gunn

Founder and CEO
Stonehaven Consulting AG

Author:

Linda Rhodes

Independent Animal Health Expert

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Author:

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Author:

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

2019 Selection Committee

This esteemed group is responsible for identifying and evaluating innovative emerging companies for presentation as part of our Japan and Asia-Pacific Company Showcases: Each of our committee members has an extensive breadth of experience and knowledge across animal health and nutrition industries and will be available for private meetings at the conference.

Author:

Dr. Tony Zi Long Tan

Founder and Managing Partner
Z-LINK BIOTECH

Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.

Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.

Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.

From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.

Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.

谭博士在动物保健领域从业超过30年,涉及各种动物品种和岗位部门,包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验,曾在美国、欧洲和亚洲(特别是中国)国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。

谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中,为牛、狗以及家禽类开发了数种疫苗,并且发表了超过50篇科学论文和研究报告。

谭博士在英特威/默沙东动物保健公司工作了超过15年,期间担任了不同职位,包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。

从2009年到2016年,谭博士在硕腾(原名辉瑞)担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易(总交易额超过一亿美元)和若干技术转让项目。其中包括中国第一个反垄断剥离项目,辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。

此外,谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。

Author:

Dr. Yuki Ujimasa, DVM, MS

President
AHRMS, Inc.

Author:

Dr. Jihong Kim

Chairman
Green Cross Veterinary Products Co., Ltd.

Dr. Jihong Kim is the chairman of Green Cross Veterinary Products Co., Ltd.. a leading animal health company in South Korea established since 1973. In his role, he is leading the international partnership and globalization initiatives.

Dr. Kim holds MBA from Harvard Business School and PhD from University of California, Berkeley. He was a professor and an associate dean of Korea Development Institute School of Public Policy and Management. He received Official Commendation from Vice Prime Minister, Ministry of Economy and was an Advisory Board Member of Ministry of Finance and Economy, South Korea.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.